Company Overview

Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a U.S.-based pharmaceutical company focused on men’s health, with primary activities centered on prescription therapeutics, digital health integration, and consumer healthcare products. The company is best known for commercializing STENDRA (avanafil), a phosphodiesterase type 5 (PDE5) inhibitor indicated for erectile dysfunction in adult men. Petros has operated in the specialty pharmaceutical and men’s wellness sectors, combining branded prescription products with telehealth-oriented distribution and patient access initiatives. Its revenue historically has been driven by prescription sales, licensing arrangements, royalties, and commercialization partnerships tied to men’s health therapeutics.

The company traces its roots to the men’s health assets formerly associated with Metuchen Pharmaceuticals and Neurotrope, Inc., which later restructured and rebranded as Petros Pharmaceuticals. Over time, Petros expanded beyond traditional pharmaceutical distribution by integrating digital healthcare strategies intended to improve access to erectile dysfunction treatment through online prescribing and fulfillment models. The company’s positioning has emphasized brand recognition around STENDRA, regulatory approvals, intellectual property related to avanafil formulations, and efforts to participate in the growing direct-to-consumer men’s health market.

Business Operations

Petros Pharmaceuticals has historically operated through a relatively focused business structure centered on branded men’s health therapeutics. Its principal commercial asset has been STENDRA, marketed in the United States for erectile dysfunction treatment. The company has also explored over-the-counter and digitally enabled healthcare opportunities connected to sexual wellness and men’s health management. Revenue generation has primarily come from product sales, licensing agreements, royalties, and strategic commercialization arrangements tied to pharmaceutical intellectual property and distribution rights.

Operations have primarily been concentrated in the United States, although the company has held or pursued international licensing and partnership relationships connected to avanafil commercialization in select foreign markets. Petros has utilized third-party manufacturing, specialty pharmacy relationships, and telemedicine integration to support commercialization efforts rather than maintaining large-scale in-house manufacturing infrastructure. The company’s operational model has included collaborations with healthcare technology providers, pharmacy fulfillment networks, and distribution partners intended to improve patient acquisition and prescription accessibility.

Strategic Position & Investments

Petros Pharmaceuticals has pursued a strategy focused on expanding access to men’s health treatments through digital healthcare channels and consumer-oriented pharmaceutical delivery models. A key strategic initiative has involved integrating prescription therapeutics with telehealth platforms to streamline physician consultation, prescription issuance, and medication fulfillment. The company has also evaluated broader consumer health opportunities associated with sexual wellness, including initiatives intended to support direct-to-consumer engagement and recurring prescription utilization.

The company’s investment focus has largely centered on commercialization efficiency, intellectual property related to avanafil products, and strategic partnerships rather than large-scale diversification into unrelated therapeutic categories. Petros has at times communicated interest in broadening its digital health footprint and leveraging data-driven patient engagement tools. Public disclosures indicate that the company has explored strategic alternatives and financing initiatives to support operations and future commercialization activities. Data regarding long-term acquisition activity and material portfolio diversification remains limited based on available public sources.

Geographic Footprint

Petros Pharmaceuticals is headquartered in the United States, with operations and commercialization activities primarily focused on the domestic healthcare market. The company’s prescription products and digital health initiatives have historically targeted U.S. consumers, healthcare providers, specialty pharmacies, and telemedicine users. Its market presence has been strongest in the American men’s health pharmaceutical sector, particularly within erectile dysfunction treatment.

International exposure has generally occurred through licensing arrangements, intellectual property rights, and commercial partnerships tied to avanafil distribution outside the United States. While the company has referenced international opportunities connected to STENDRA and related men’s health assets, publicly available information indicates that its direct operational footprint abroad has been comparatively limited relative to larger multinational pharmaceutical firms. Data inconclusive based on available public sources regarding the scale of current international commercialization activities.

Leadership & Governance

Petros Pharmaceuticals has been led by executives with backgrounds in pharmaceuticals, healthcare commercialization, specialty therapeutics, and corporate finance. Leadership strategy has generally emphasized commercialization of men’s health assets, expansion of digital healthcare access, operational restructuring, and capital management. Corporate governance has reflected the company’s status as a publicly traded specialty pharmaceutical company subject to U.S. securities reporting and board oversight requirements.

Key executives and leadership figures have included:

• Fady Boctor – Chairman of the Board
• Sergey Kalinichenko – Chief Executive Officer
• Jatinder Dhaliwal – Chief Financial Officer
• John Shulman, M.D. – Former President and Chief Medical Officer

The company’s leadership approach has focused on integrating pharmaceutical commercialization with telehealth-enabled distribution and consumer healthcare accessibility. Public filings and corporate communications have consistently highlighted efforts to optimize operational efficiency, strengthen commercialization channels, and evaluate strategic growth opportunities within the men’s health sector.